Short answer
Aardvark Therapeutics, Inc. (AARD) filed its Q3 2025 10-Q quarterly report on Nov 13, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $0 with net income of −$16M.
Q3 2025 key financials · XBRL
- Revenue
- $0
- Net income
- −$16M
- −13.6% QoQ
- EPS (diluted)
- −$0.76
- −16.9% QoQ
Source: XBRL data from the Aardvark Therapeutics, Inc. (AARD) Q3 2025 10-Q on SEC EDGAR. USD.
Aardvark Therapeutics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk: Material weakness in internal control over financial reporting identified, may affect accurate or timely financial reporting and investor confidence
- Material update: Net loss increased from $11.8M to $40.0M for nine months ended Sept 30, driven by higher R&D and G&A expenses
- Regulatory risk: FDA regulatory approval for ARD-101 Phase 3 trial and NDA submission remain lengthy, unpredictable, with potential additional trial requirements
- Operational risk: Reliance on third parties for clinical trials and manufacturing may delay development if contractual or regulatory standards not met
- Financial risk: Cash, cash equivalents, and short-term investments $126.4M as of Sept 30, expected to fund operations into 2027 but may require earlier capital raise
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Aardvark Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.